
DEVELOPMENT PROGRAMS - SOLID TUMOR




*In collaboration with Nanjing Leads Biolabs. †In collaboration with SpringWorks Therapeutics.


PAGE 1 OF 2

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BRAF, B-Raf proto-oncogene; CEA, carcinoembryonic antigen; CCR8, C-C chemokine receptor 8; CRC, colorectal cancer; DGKζ, diacylglycerol kinase zeta, and HNSCC; dMMR, mismatch repair deficient; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HPK1, hematopoietic progenitor kinase 1; LAG-3, lymphocyte-activation gene 3; MSI, microsatellite instability; MSI-H, microsatellite instability cancer; PD-L1, programmed death-ligand 1; PIK38, phosphoinositide 3-kinase delta; SMAC, Second Mitochondrial-derived Activator of Caspases; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM-3, T cell immunoglobulin and mucin domain-containing protein 3; VEGF, vascular endothelial growth factor.



DEVELOPMENT PROGRAMS - SOLID TUMOR



[‡]Clinical collaboration with Hutchison Medipharma International.

§In collaboration with Zymeworks, Inc.

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BTC, biliary tract cancer; CRC, colorectal cancer; CSF-1R, colony stimulating factor-1 receptor; DKK1, Dickkopf-1; EC, endometrial cancer; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor-2; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; UBC, urothelial bladder cancer; VEGFR, vascular endothelial growth factor receptors.

